Vice President J.D. Vance has called on the Department of Justice (DOJ) to investigate health care providers accused of using fraudulent billing codes to obtain insurance coverage for transgender medical interventions in children. This action follows the release of a Department of Health and Human Services (HHS) report that details alleged misconduct by doctors and hospitals in the billing and provision of pediatric transgender care.
Explainer The Evolving Landscape of American Health Care Legislation
The move marks a significant escalation in the ongoing scrutiny of transgender medical care for minors. Vance stated that providers who intentionally miscode treatments to secure insurance payments for gender-transitioning interventions "should go to prison."
The HHS report, titled Wolves in White Coats, alleges that since 2019, doctors and hospitals have filed approximately $120 million in insurance claims for child transgender procedures. These claims include more than 5,500 surgeries and 8,500 courses of opposite-sex hormones or puberty blockers. The report further claims that over 225 hospitals and health systems established pediatric transgender clinics between 2015 and 2025, and that these clinics used misleading or potentially fraudulent diagnostic and procedural codes to obtain insurance payments for interventions such as mastectomies and vaginoplasties.
DOJ Referral and Vance's Statement
Vance sent a formal letter to Attorney General Todd Blanche, referring the HHS report and its allegations to the Justice Department. In the letter, Vance called for an investigation into whether providers violated federal fraud and conspiracy laws by misrepresenting treatments in insurance claims. "When providers miscode treatments in order to secure insurance coverage for gender-transitioning interventions that insurance would not otherwise cover, they should be held accountable," Vance wrote. "If they have done so intentionally, thereby perpetrating fraud on Medicaid or on private insurers, they should go to prison."
"This miscoding has allowed hospitals to bill insurance companies tens of millions of dollars for medication like puberty-blocking drugs."
— J.D. Vance, Vice President
According to the HHS report, doctors used the generic code for "endocrine disorder, unspecified" to provide puberty blockers to hundreds of children ages 9 to 17, even though fewer than 5 percent of patients with that code actually had endocrine disorders. This practice generated $42.6 million in insurance claims, with about $7.8 million paid by Medicaid. Another code, "precocious puberty," was used to justify puberty blockers for children well beyond the typical diagnosis age, including teenagers up to 18 years old at Children’s Hospital of Philadelphia.
Alleged Financial Incentives and Patient Impact
The HHS report argues that financial incentives have played a significant role in the rapid expansion of pediatric gender clinics. It describes a shift in pediatric departments from low-profit margins to what it calls a "new stream of continuous revenue" from gender-related interventions. The report estimates that lifetime health care costs for patients who begin transitioning as children can reach $75,000 without surgeries and up to $170,000 with surgeries. These figures do not include additional therapies such as fertility preservation or detransition attempts.
The report includes eight first-hand accounts from parents and children, which describe weak clinical safeguards, rushed processes, minimal psychological evaluation, and pressure on parents to consent to medical interventions. The report criticizes what it characterizes as a failure of oversight at multiple levels, resulting in long-term consequences for patients.
Response and Broader Context
The allegations outlined in the HHS report come amid a broader national debate over the regulation of transgender medical care for minors. Critics argue that financial and ideological pressures have compromised patient safety and the integrity of medical decision-making. The HHS report states, "Parents count on America’s pediatric hospitals, medical associations, and federal regulatory agencies to value science over ideology and people over profit when recommending medical procedures."
Supporters of pediatric transgender care have not responded to the latest allegations. The Federalist Radio Hour, which has covered related issues, has highlighted the political and cultural dimensions of the debate but did not feature a direct response from medical organizations or providers named in the HHS report.
The Justice Department has not yet announced whether it will open a formal investigation based on Vance's referral. The situation remains fluid, with ongoing attention from lawmakers, advocacy groups, and the public as the debate over pediatric transgender care continues to unfold.
The HHS report, which serves as the basis for Vance's referral, is available to the public and provides detailed data and case studies regarding the alleged practices. The report's findings are expected to fuel further discussion and potential policy responses regarding the oversight and regulation of transgender medical care for minors.
